Small Interfering RNAs (siRNAs) Therapeutics Market Size to Reach USD 1,987.5 million in 2032

(MENAFN- Navistrat Analytics) September 19, 2025- Interfering RNA (siRNA) therapeutics market. The American Cancer Society estimates that in 2025, approximately 67,440 individuals in the United States (34,950 men and 32,490 women) will be diagnosed with pancreatic cancer, and around 51,980 people (27,050 men and 24,930 women) will die from the disease. The average lifetime risk of developing pancreatic cancer is about one in 56 for men and one in 60 for women.

Advancements in drug delivery technologies are showing great potential to enhance siRNA-based therapies, paving the way for a new class of pharmaceuticals called nano-siRNA drugs. Unlike small molecule therapeutics and monoclonal antibodies, siRNA provides a distinct advantage by precisely silencing target genes through complete Watson-Crick base pairing with mRNA.

In March 2025, Alnylam Pharmaceuticals, Inc., a leader in RNA interference (RNAi) therapeutics, announced that the U.S. Food and Drug Administration (FDA) approved Qfitlia (fitusiran). This marks Alnylam's sixth RNAi therapeutic to receive FDA approval in the United States, and the first and only therapy designed to lower antithrombin (AT), a protein that inhibits blood clotting. The aim of Qfitlia is to enhance thrombin generation, restore hemostatic balance, and prevent bleeding episodes.

Small interfering RNA (siRNA) presents a powerful method for gene silencing by selectively targeting specific genes. Although several siRNA-based therapies have already gained FDA approval, their widespread clinical use remains limited by significant biological barriers. The hydrophilic and negatively charged nature of siRNA molecules creates a major challenge in delivering them effectively to target cells.

Segments market overview and growth Insights
Based on the product and service, the Small Interfering RNAs (siRNAs) therapeutics market is segmented into therapeutic siRNA drugs, reagents & kits, and services. Therapeutic siRNA drugs segment contributed the largest share in 2024. The clinical application of RNA interference (RNAi) biological mechanisms has enabled the emergence of a new and growing class of RNA-based therapies. These treatments function by modulating the expression of specific target genes at the post-transcriptional level. The development of additional RNAi therapies is accelerating due to the increasing number of approved siRNA drugs and the expanding range of disease indications they address.

Regional market overview and growth insights
North America held the largest market share in the Small Interfering RNAs (siRNAs) Therapeutics market in 2024. The market is being driven by rising prevalence of genetic and rare diseases, advancements in RNA delivery technologies improving therapeutic efficacy, and increasing pipeline of siRNA-based drugs with regulatory approvals. According to the Centers for Disease Control and Prevention (CDC), the exact prevalence of hemophilia in the United States is not well established, but it is estimated that around 33,000 individuals assigned male at birth are living with the condition nationwide. Hemophilia predominantly affects those assigned male at birth, with over half of hemophilia A cases being classified as severe.

Competitive Landscape and Key Competitors
The Small Interfering RNAs (siRNAs) Therapeutics market is characterized by a fragmented structure, with many competitors holding a significant share of the market. list of major players included in the Small Interfering RNAs (siRNAs) Therapeutics market report are:

o Atalanta Therapeutics
o Horizon Discovery
o Alnylam Pharmaceuticals, Inc.
o Creative Biolabs
o Aro Biotherapeutics Company
o Novartis AG
o Eleven Therapeutics
o Switch Therapeutics
o Judo Bio
o City Therapeutics
o Sirius Therapeutics
o Rona Therapeutics

Major strategic developments by leading competitors
CRISPR Therapeutics: In May 2025, CRISPR Therapeutics, a biopharmaceutical company specializing in developing groundbreaking gene-based treatments for serious diseases, announced a strategic partnership with Sirius Therapeutics, a clinical-stage biotech firm focused on innovative small interfering RNA (siRNA) therapies for global markets. The collaboration aims to develop and commercialize siRNA-based therapies.

Sirius Therapeutics: In May 2025, Sirius Therapeutics revealed the successful completion of approximately USD 50 million in Series B2 funding. This capital will support the further clinical development of the company’s advanced siRNA therapies targeting cardiometabolic diseases, along with the ongoing advancement of its next-generation RNA delivery platform.

Navistrat Analytics has segmented the Small Interfering RNAs (siRNAs) Therapeutics market based on product and service, delivery modality, application, end-use, and region:
• Product and Service Outlook (Revenue, USD Million; 2022-2032)
o Therapeutic siRNA Drugs
o Reagents & Kits
o Services

• Delivery Modality Outlook (Revenue, USD Million; 2022-2032)
o Conjugate-based delivery
o Nanoparticle-based delivery
o Biological carriers
o Others

• Application Outlook (Revenue, USD Million; 2022-2032)
o Therapeutics
o Research

• End-Use Outlook (Revenue, USD Million; 2022-2032)
o Hospitals and Clinics
o Pharmaceutical and Biotechnology Companies
o Research Institutes and Academic Centers
o Contract Research Organizations (CROs)

• Regional Outlook (Revenue, USD Million; 2022-2032)
o North America
a. U.S.
b. Canada
c. Mexico
o Europe
a. Germany
b. France
c. U.K.
d. Italy
e. Spain
f. Benelux
g. Nordic Countries
h. Rest of Europe
o Asia Pacific
a. China
b. India
c. Japan
d. South Korea
e. Oceania
f. ASEAN Countries
g. Rest of APAC
o Latin America
a. Brazil
b. Rest of LATAM
o Middle East & Africa
a. GCC Countries
b. South Africa
c. Israel
d. Turkey
e. Rest of MEA

@~Navistrat Analytics

MENAFN19092025008152017457ID1110084148